Exacerbations requiring steroids, antibiotics or both · patients with stable chronic obstructive pulmonary disease
Aclidinium bromide showed no clear difference in exacerbations requiring steroids, antibiotics or both compared with placebo (moderate certainty).
1 finding from 1 review
Quality of life: number of participants with clinically significant improvement (≥ 4 units) in SGRQ total score · patients with stable chronic obstructive pulmonary disease
Aclidinium bromide leads to higher quality of life Number of patients who achieved at least 4 units… compared with placebo (high certainty).
1 finding from 1 review
Six‐minute walk distance · patients with stable chronic obstructive pulmonary disease
1 finding from 1 review
Hospital admission (exacerbation) · patients with stable chronic obstructive pulmonary disease
Aclidinium bromide leads to lower hospital admissions due to exacerbations compared with placebo (high certainty).
1 finding from 1 review
Non‐fatal serious adverse events · patients with stable chronic obstructive pulmonary disease
Aclidinium bromide showed no clear difference in non‐fatal serious adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Protection from experiencing an asthma exacerbation of any cause over the influenza season ‐ children (over 6 years of age) given inactivated influenza vaccine · people with asthma
1 finding from 1 review
Protection from experiencing an influenza‐related asthma exacerbation over the influenza season ‐ children (over 6 years of age) given inactivated influenza vaccine · people with asthma
1 finding from 1 review
Asthma exacerbation (adverse effects) caused by inactivated influenza vaccine, measured in the first 2 weeks following vaccination ‐ children (over 3 years of age) given inactivated influenza vaccine · people with asthma
1 finding from 1 review
Protection from experiencing an asthma exacerbation of any cause over the influenza season ‐ adults given inactivated influenza vaccine · people with asthma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Protection from experiencing an influenza‐related asthma exacerbation over the influenza season ‐ adults given inactivated influenza vaccine · people with asthma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Asthma exacerbation (adverse effects) caused by inactivated influenza vaccine, measured in the first 2 weeks following vaccination ‐ adults given inactivated influenza vaccine · people with asthma
1 finding from 1 review
Change in Morning PEF after 12 months (% predicted) · asthmatics with sensitivity to house dust mite
MHRV showed no clear difference in change in Morning PEF after 12 months (% predicted) compared with placebo (moderate certainty).
1 finding from 1 review
Change in Evening PEF after 12 months (% predicted) · asthmatics with sensitivity to house dust mite
MHRV probably leads to higher change in Evening PEF after 12 months (% predicted) compared with placebo (moderate certainty).
1 finding from 1 review
FEV1 · asthmatics with sensitivity to house dust mite
MHRV showed no clear difference in change in FEV1 after 12 months (% predicted) compared with placebo (moderate certainty).
1 finding from 1 review
SGRQ Total SGRQ (Total) Score. Scale from: 0 to 100. Lower score indicates better quality of life. · asthmatics with sensitivity to house dust mite
MHRV showed no clear difference in quality of life SGRQ Scale from 0 to 100 (0 on the scale is better) compared with placebo (moderate certainty).
1 finding from 1 review
Mean exacerbations requiring a course of oral corticosteroids · asthmatics with sensitivity to house dust mite
MHRV showed no clear difference in exacerbations needing oral steroids compared with placebo (moderate certainty).
1 finding from 1 review
Exacerbations leading to ED visits · asthmatics with sensitivity to house dust mite
MHRV showed no clear difference in exacerbations needing ED visit compared with placebo (moderate certainty).
1 finding from 1 review
Exacerbations needing hospitalisation · asthmatics with sensitivity to house dust mite
MHRV showed no clear difference in exacerbations needing hospitalisation compared with placebo (moderate certainty).
1 finding from 1 review
Maximal percentage fall in FEV1 · exercise‐induced asthma
1 finding from 1 review
Number of participants with an FEV1 fall > 10% · exercise‐induced asthma
Beta2‐agonists probably leads to lower number of participants with an FEV1 fall > 10% compared with placebo (single administration) (moderate certainty).
1 finding from 1 review